A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 4, 2012, Pages 496-503

  Galzerano, Domenico ^a   Di Michele, Sara ^b   Paolisso, Giuseppe ^c   Tuccillo, Bernardino ^d   Lama, Diana ^c   Carbotta, Sabino ^b   Cittadini, Antonio ^e   Tedesco, Michele Adolfo ^c   Gaudio, Carlo ^b  

^a San Gennaro Hospital   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Division of Cardiology   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Angiotensin II receptor blocker; atrial fibrillation; hypertension; stroke; telmisartan

Indexed keywords

CARVEDILOL; TELMISARTAN;

ARTICLE; ASTHMA; BORDERLINE HYPERTENSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE MASS; HEART SIZE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BENZOATES; CARBAZOLES; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORGAN SIZE; PROPANOLAMINES; RECURRENCE;

EID: 84870030808     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312443909     Document Type: Article

References (39)

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation. 2004 ; 110: 1042-1046
2. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population based-estimates. Am J Cardiol. 1998 ; 82: 2N - 9N
3. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002 ; 113: 359-364
4. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002 ; 113: 365-370
5. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: Changes over three decades. J Am Coll Cardiol. 2003 ; 42: 93-100
6. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995 ; 98: 476-484
7. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003 ; 41: 218-223
8. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995 ; 1: 355-363
9. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999 ; 100: 376-380
10. Solti F, Vecsey T, Kékesi V, et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989 ; 23: 882-886
11. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 1997 ; 96: 1686-1695
12. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000 ; 101: 2612-2617
13. Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000 ; 35: 1669-1677
14. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin. 2000 ; 18: 435-442
15. Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens. 2000 ; 9: 403-411
16. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol. 2005 ; 45: 1832-1839
17. Maggioni AP, Latini R, Carson PE, et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005 ; 149: 548-557
18. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005 ; 45: 712-719
19. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation. 2002 ; 106: 331-336
20. Galzerano D, Capogrosso C, De Michele S, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 ; 6: 113-133
21. Mattioli AV, Zennaro M, Bonatti S, et al. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol. 2004 ; 97: 383-388
22. Martina B, Dieterle T, Sigle JP, et al. Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology. 2003 ; 99: 169-170
23. Galzerano D, Tammaro P, Cerciello A, et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: A multicentre study. J Hum Hypertens. 2004 ; 18: 53-59
24. Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass: A multicenter, randomized, longitudinal study. Am J Hypertens. 2005 ; 18: 1563-1569
25. Verdecchia P, Sleight P, Mancia G, et al. ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009 ; 120: 1380-1389
26. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358: 1547-1559
27. Yusuf S, Teo KK, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008 ; 372: 1174-1183
28. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol. 2003 ; 42: 1944-1951
29. Katritsis DG, Panagiotakos DB, Karvouni E, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol. 2003 ; 92: 1116-1119
30. Merritt JC, Niebaur M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol. 2003 ; 92: 735-736
31. Kanoupakis EM, Manios EG, Mavrakis HE, et al. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol. 2004 ; 94: 659-662
32. McMurray J, Køber I, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005 ; 45: 525-530
33. Fuster V, Rydén LE, Cannom DS, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 ; 114: e257 - e354
34. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011 ; 57: e101 - e198
35. Disertori M, Alboni P, Botto GL, et al. Linee guida sul trattamento della fibrillazione atriale AIAC. G Ital Aritm Cardiostim. 2006 ; 9: 1-71
36. Raviele A, Disertori M, Alboni P, et al. Linee guida AIAC 2010 per la gestione e il trattameto fibrillazione atriale. G Ital Cardiol. 2010 ; 13: 61-157
37. Lang RM, Bierig M, Devereux RB, et al. Recommendations for Chamber Quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 ; 18: 1440-1463
38. Galetta F, Franzoni F, Fallahi P, et al. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother. 2010 ; 64: 516-520
39. Celik T, Iyisoy A, Kursaklioglu H, et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: A randomized clinical study. Clin Cardiol. 2005 ; 28: 298-302